Findings from Taizhou University in Prostate Cancer Reported (Heparanase Inhibitor Ogt 2115 Induces Prostate Cancer Cell Apoptosis Via the Downregulation of Mcl-1).
In: Drug Week, 2024-02-16, S. 313-313
serialPeriodical
Zugriff:
A recent report from Taizhou University in Zhejiang, China, discusses the role of heparanase (HPSE) in prostate cancer. HPSE is an enzyme that promotes tumor cell evasion of apoptosis, or programmed cell death. The study found that the HPSE inhibitor OGT 2115 induced apoptosis in prostate cancer cells by downregulating the antiapoptotic protein MCL-1. In vivo experiments showed that OGT 2115 inhibited tumor growth in mice. These findings suggest that targeting HPSE with OGT 2115 could be a potential therapeutic strategy for prostate cancer. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Findings from Taizhou University in Prostate Cancer Reported (Heparanase Inhibitor Ogt 2115 Induces Prostate Cancer Cell Apoptosis Via the Downregulation of Mcl-1).
|
---|---|
Zeitschrift: | Drug Week, 2024-02-16, S. 313-313 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Sonstiges: |
|